All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

EHA2022 abstracts: What's hot in ALL?

Jun 6, 2022

Bookmark this article

To help navigate the exciting content being presented at the EHA2022 Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies


Baseline gene expression analysis of relapsed acute B-lymphoblastic leukemia patients treated with inotuzumab ozogamicin


Blinatumomab and donor lymphocyte infusion (DLI) for molecular relapse after hematopoietic stem cell transplantation in pediatric patients


Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed B-cell acute lymphoblastic leukemia: updates from a phase II trial


Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia (MPAL) diagnosed and treated in the last ten years. A CAMPUS-ALL study


Improved overall survival and MRD clearance with blinatumomab vs chemotherapy as pre-transplant consolidation in pediatric high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL)


A phase II study of inotuzumab ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia


A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia


Hyper-CVAD with sequential blinatumomab, with or without inotuzumab ozogamicin, in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia


Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial


National pegaspargase-modified risk-oriented program for Philadelphia-negative adult acute lymphoblastic leukemia/lymphoblastic lymphoma (Ph− ALL/LL). GIMEMA LAL 1913 final results


Ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results from a phase II study

Treatment for relapsed/refractory ALL

Real-world evidence

Biomarkers and biology

EHA2022 abstracts

To download this document, click below.

Download here

More about...


Subscribe to get the best content related to ALL delivered to your inbox